



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/759,328		
		Filing Date	January 16, 2004		
		First Named Inventor	Said M. Sebti		
		Group Art Unit	1636		
		Examiner Name	Maruch		
Sheet	1	of	5	Attorney Docket Number	USF-T144XCZ1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
mm	R1	ADNANE, J. <i>et al.</i> "Suppression of Rho B expression in invasive carcinoma from head and neck cancer patients" <i>Clin Cancer Res</i> , 2002, 8:2225-2232.	
	R2	ALIMANDI, M. <i>et al.</i> "Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas" <i>Oncogene</i> , 1995, 10:1813-1821.	
	R3	ARBOLEDA, M.J. <i>et al.</i> "Overexpression of AKT2/protein kinase B $\beta$ leads to up-regulation of $\beta$ 1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells" <i>Cancer Res</i> , 2003, 63:196-206.	
	R4	BUDAY, L. and DOWNWARD, J. "Epidermal growth factor regulates p21 <sup>ras</sup> through the formation of a complex of receptor, Grb2 adaptor protein, and Sos nucleotide exchange factor" <i>Cell</i> , 1993, 73:611-620.	
	R5	CHEN, Z. <i>et al.</i> "Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice" <i>J Biol Chem</i> , 2000, 275(24):17974-17978.	
	R6	DAVIES, M.A. <i>et al.</i> "Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells" <i>Clin Cancer Res</i> , 2002, 8:1904-1914.	
	R7	DU, W. and PRENDERGAST, G.C. "Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors" <i>Cancer Res</i> , 1999, 59:5492-5496.	
	R8	DU, W. <i>et al.</i> "Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB" <i>Mol Cell Biol</i> , 1999, 19(3):1831-1840.	
	R9	FORGET, M.A. <i>et al.</i> "The expression of Rho proteins decreases with human brain tumor progression: potential tumor markers" <i>Clin Exp Metastasis</i> , 2002, 19(1):9-15, abstract.	
	R10	FRITZ, G. and KAINA, B. "rhoB encoding a UV-inducible Ras-related small GTP-binding protein is regulated by GTPases of the Rho family and independent of JNK, ERK, and p38 MAP kinase" <i>J Biol Chem</i> , 1997, 272(49):30637-30644.	
	R11	FRITZ, G. <i>et al.</i> "The Ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments" <i>J Biol Chem</i> , 1995, 270(42):25172-25177.	
	R12	HALL, A. "Rho GTPases and the actin cytoskeleton" <i>Science</i> , 1998, 279(5350):509-514.	
mm	R13	HUNTER, T. "Oncoprotein networks" <i>Cell</i> , 1997, 88:333-346.	

Examiner Signature	<i>Maruch</i>	Date Considered	5/24/05
--------------------	---------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/759,328		
		Filing Date	January 16, 2004		
		First Named Inventor	Said M. Sebti		
		Group Art Unit	1636		
Examiner Name					
Sheet	2	of	5	Attorney Docket Number	USF-T144XCZ1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MM	R14	JAHNER, D. and HUNTER, T. "The <i>ras</i> -related gene <i>rhoB</i> is an immediate-early gene inducible by v-Fps, epidermal growth factor, and platelet-derived growth factor in rat fibroblasts" <i>Mol Cell Biol</i> , 1991, 11(7):3682-3690.	
	R15	JIANG, K. <i>et al.</i> "Regulation of Akt-dependent cell survival by Syk and Rac" <i>Blood</i> , 2003, 101:236-244.	
	R16	KHOSRAVI-FAR, R. and DER, C.J. "The Ras signal transduction pathway" <i>Cancer Metastasis Rev</i> , 1994, 13:67-89.	
	R17	KHOSRAVI-FAR, R. <i>et al.</i> "Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation" <i>Mol Cell Biol</i> , 1995, 15(11):6443-6453.	
	R18	KIM, D. <i>et al.</i> "Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production" <i>Faseb J</i> , 2001, 15:1953-1962.	
	R19	KUBIATOWSKI, T. <i>et al.</i> "Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas" <i>J Neurosurg</i> , 2001, 95:480-488.	
	R20	LEBOWITZ, P.F. <i>et al.</i> "Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity" <i>Mol Cell Biol</i> , 1995, 15(12):6613-6622.	
	R21	LIU, A. <i>et al.</i> "RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors" <i>Mol Cell Biol</i> , 2000, 20(16):6105-6113.	
	R22	LIU, A. <i>et al.</i> "RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage" <i>Proc Natl Acad Sci USA</i> , 2001, 98(11):6192-6197.	
	R23	LUETTEKE, N.C. <i>et al.</i> "The mouse <i>waved-2</i> phenotype results from a point mutation in the EGF receptor tyrosine kinase" <i>Genes Dev</i> , 1994, 8:399-413.	
	R24	NAKAMURA, T. <i>et al.</i> "Cloning of the RhoB gene from the mouse genome and characterization of its promoter region" <i>Biochem. Biophys. Res. Commun.</i> , 1996, 226(3):688-694, abstract.	
	R25	PARK, B-K. <i>et al.</i> "Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells" <i>Cancer Res</i> , 2001, 61:7647-7653.	
MM	R26	PRUITT, K. and DER, C.J. "Ras and Rho regulation of the cell cycle and oncogenesis" <i>Cancer Lett.</i> , 2001, 171(1):1-10.	

Examiner Signature	<i>M. March</i>	Date Considered	5/25/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/759,328		
		Filing Date	January 16, 2004		
		First Named Inventor	Said M. Sebti		
		Group Art Unit	1636		
		Examiner Name			
Sheet	3	of	5	Attorney Docket Number	USF-T144XCZ1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MM	R27	QUILLIAM, L.A. <i>et al.</i> "Identification of residues critical for Ras(17N) growth-inhibitory phenotype and for Ras interaction with guanine nucleotide exchange factors" <i>Mol Cell Biol</i> , 1994, 14(2):1113-1121.	
	R28	STEWART, A.L. <i>et al.</i> "PI3K blockade by Ad-PTEN inhibits invasion and induces apoptosis in radial growth phase and metastatic melanoma cells" <i>Mol Med</i> , 2002, 8(8):451-461.	
	R29	SYMONS, M. and SETTLEMAN, J. "Rho family GTPases: more than simple switches" <i>Trends Cell Biol</i> , 2000, 10(10):415-419.	
	R30	TURKSON, J. <i>et al.</i> "Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein" <i>Mol Cell Biol</i> , 1999, 19(11):7519-7528.	
	R31	VAN AELST, L. and D'SOUZA-SCHOREY, C. "Rho GTPases and signaling networks" <i>Genes Dev</i> , 1997, 11(18):2295-2322.	
	R32	VLAHOS, C.J. <i>et al.</i> "A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)" <i>J Biol Chem</i> , 1994, 269(7):5241-5248.	
	R33	YANO, H. <i>et al.</i> "Biochemical and pharmacological studies with KT7692 and LY294002 on the role of phosphatidylinositol 3-kinase in FcεRI-mediated signal transduction" <i>Biochem J</i> , 1995, 312(Pt 1):145-150.	
	R34	ZOHN, I.M. <i>et al.</i> "Rho family proteins and Ras transformation: the RHOad less traveled gets congested" <i>Oncogene</i> , 1998, 17:1415-1438.	
	R35	MCCORMICK, F. <i>Nature</i> , 1993, 363:15-16.	
	R36	CAMPBELL, S.L. <i>et al.</i> <i>Oncogene</i> , 1998, 17:1395-1413.	
	R37	BARBACID, M. <i>Annu. Rev. Biochem.</i> , 1987, 56:779-827.	
	R38	BOS, J.L. <i>Cancer Res.</i> , 1989, 49:4682-4689.	
MM	R39	OLSON, M.F. <i>et al.</i> <i>A. Science</i> , 1995, 269:1270-1272.	

Examiner Signature	<i>M. March</i>	Date Considered	5/25/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/759,328		
		Filing Date	January 16, 2004		
		First Named Inventor	Said M. Sebti		
		Group Art Unit	1636		
		Examiner Name			
Sheet	4	of	5	Attorney Docket Number	USF-T144XCZ1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MM	R40	QIU, R.G. et al. <i>Nature</i> , 1995, 374:457-459.	
	R41	MELLOR, H. et al. <i>J. Biol. Chem.</i> , 1998, 273:4811-4814.	
	R42	ZHANG, F.L. et al. <i>Annu. Rev. Biochem.</i> , 1996, 65:241-269.	
	R43	LEBOWITZ, P.F. et al. <i>J. Biol. Chem.</i> , 1997, 272:15591-15594.	
	R44	SEBTI, S.M. et al. <i>Pharmacol. Ther.</i> , 1997, 272:15591-15594.	
	R45	GIBBS, J.B. et al. <i>Annu. Rev. Pharmacol. Toxicol.</i> , 1997, 37:143-166.	
	R46	COX, A.D. et al. <i>Biochim. Biophys. Acta.</i> , 1997, 1333:F51-F71.	
	R47	LEBOWITZ, P.F. et al. <i>Oncogene</i> , 1998, 17:1439-1445.	
	R48	CHEN, Z. et al. "Farnesylated and geranylgeranylated RhoB suppress the transformation of PANC-1 human pancreatic cancer cells" Proceedings of the 91 <sup>st</sup> Annual Meeting of the American Association of Cancer Research, Vol. 14, page 220, abstract no. 1402.	
	R49	LIU and JESSELL "A role for rhoB in the delamination of neural crest cells from the dorsal neural tube" <i>Development</i> , 1998, 125:5055-5067.	
	R50	LEBOWITZ et al. "Farnesyltransferase inhibitors alter the prenylations and growth-stimulating function of RhoB" <i>JBC</i> , 1997, 272(25):15591-15594.	
	R51	MENG and EL-DEIRY "Tumor suppressor genes as targets for cancer gene therapy" <i>Gene Therapy of Cancer</i> , Chapter 1, pages 3-18.	
MM	R52	VERMA and SOMIA "Gene therapy-promises, problems and prospects" <i>Nature</i> , 1997, 389:239-242.	

Examiner Signature	<i>M. Marich</i>	Date Considered	5/25/05
--------------------	------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/759,328		
		Filing Date	January 16, 2004		
		First Named Inventor	Said M. Sebtì		
		Group Art Unit	1636		
		Examiner Name			
Sheet	5	of	5	Attorney Docket Number	USF-T144XCZ1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MM	R53	MARSHALL "Second child in French trial is found to have aleukemia" <i>Science</i> , 2003, 299:320.	
MM	R54	TORCHILIN and LUKYANOV "Peptide and protein drug delivery to and into tumors: challenges and solutions" <i>Drug Discover Today</i> , 2003, 8:259-265.	
	R55		
	R56		
	R57		
	R58		
	R59		
	R60		
	R61		
	R62		
	R63		
	R64		
	R65		

Examiner Signature	<i>M. Marich</i>	Date Considered	5/25/05
--------------------	------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.